Chemed Co. (NYSE:CHE) Shares Acquired by Occudo Quantitative Strategies LP

Occudo Quantitative Strategies LP raised its holdings in Chemed Co. (NYSE:CHE - Free Report) by 214.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,652 shares of the company's stock after purchasing an additional 1,126 shares during the quarter. Occudo Quantitative Strategies LP's holdings in Chemed were worth $875,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of CHE. UMB Bank n.a. raised its holdings in Chemed by 300.0% in the 4th quarter. UMB Bank n.a. now owns 52 shares of the company's stock valued at $28,000 after buying an additional 39 shares during the period. Atala Financial Inc acquired a new stake in shares of Chemed during the fourth quarter valued at about $29,000. CBIZ Investment Advisory Services LLC lifted its holdings in shares of Chemed by 64.7% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 56 shares of the company's stock worth $30,000 after acquiring an additional 22 shares during the last quarter. Trust Co. of Vermont purchased a new position in shares of Chemed during the 4th quarter worth approximately $34,000. Finally, Tortoise Investment Management LLC increased its holdings in Chemed by 77.3% in the 4th quarter. Tortoise Investment Management LLC now owns 78 shares of the company's stock valued at $41,000 after purchasing an additional 34 shares during the last quarter. Institutional investors and hedge funds own 95.85% of the company's stock.

Chemed Stock Performance

Shares of Chemed stock traded down $1.40 during trading hours on Monday, reaching $578.46. 22,797 shares of the company were exchanged, compared to its average volume of 101,427. The firm has a market cap of $8.46 billion, a PE ratio of 29.23, a PEG ratio of 2.15 and a beta of 0.59. Chemed Co. has a 1 year low of $512.12 and a 1 year high of $623.61. The stock's fifty day moving average is $586.22 and its 200 day moving average is $564.37.

Chemed (NYSE:CHE - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The company reported $5.63 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.04. Chemed had a return on equity of 27.86% and a net margin of 12.69%. The business had revenue of $646.94 million during the quarter, compared to the consensus estimate of $641.78 million. During the same period in the previous year, the company posted $5.20 earnings per share. The business's revenue for the quarter was up 9.8% on a year-over-year basis. Research analysts expect that Chemed Co. will post 21.43 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Spencer S. Lee sold 1,500 shares of the business's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $577.99, for a total transaction of $866,985.00. Following the completion of the sale, the executive vice president now owns 14,627 shares in the company, valued at approximately $8,454,259.73. The trade was a 9.30% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin J. Mcnamara sold 1,000 shares of the company's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $615.33, for a total transaction of $615,330.00. Following the completion of the transaction, the chief executive officer now owns 101,679 shares of the company's stock, valued at approximately $62,566,139.07. The trade was a 0.97% decrease in their position. The disclosure for this sale can be found here. Insiders sold 7,500 shares of company stock valued at $4,401,120 in the last ninety days. Insiders own 3.29% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CHE. Royal Bank of Canada raised their price target on Chemed from $667.00 to $674.00 and gave the stock an "outperform" rating in a research report on Monday, April 28th. StockNews.com upgraded shares of Chemed from a "hold" rating to a "buy" rating in a research note on Friday, March 7th.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.